Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:ADMP

Adamis Pharmaceuticals (ADMP) Stock Price, News & Analysis

Adamis Pharmaceuticals logo

About Adamis Pharmaceuticals Stock (NASDAQ:ADMP)

Key Stats

Today's Range
N/A
50-Day Range
$0.77
$3.99
52-Week Range
N/A
Volume
119,800 shs
Average Volume
811,695 shs
Market Capitalization
$7.26 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease. Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose. The company is headquartered in San Diego, California.

Receive ADMP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adamis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ADMP Stock News Headlines

DMK Pharmaceuticals Corp DMK
2 sentences that change everything you THOUGHT you knew about trading
If you're like most people, on Friday morning you'll probably follow your set routine: Wake up... eat breakfast... go to work... But if you say these two sentences to your broker... you could collect as much as $1,250 on Friday... no matter where you live, whether you're working or already retired. It all has to do with a unique stock market secret that's worked 97% of the time for the past 8 years running.
See More Headlines

ADMP Stock Analysis - Frequently Asked Questions

Adamis Pharmaceuticals Co. (NASDAQ:ADMP) released its earnings results on Thursday, March, 31st. The specialty pharmaceutical company reported ($4.20) earnings per share for the quarter, missing analysts' consensus estimates of ($2.80) by $1.40. Adamis Pharmaceuticals had a negative net margin of 502.73% and a negative trailing twelve-month return on equity of 420.53%.

Adamis Pharmaceuticals shares reverse split before market open on Monday, May 22nd 2023. The 1-70 reverse split was announced on Monday, May 22nd 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 22nd 2023. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Adamis Pharmaceuticals investors own include Sangamo Therapeutics (SGMO), Vaxart (VXRT), Sorrento Therapeutics (SRNE), Tonix Pharmaceuticals (TNXP), Aurinia Pharmaceuticals (AUPH), Corbus Pharmaceuticals (CRBP) and FuelCell Energy (FCEL).

Company Calendar

Last Earnings
3/31/2022
Today
11/04/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Current Symbol
NASDAQ:ADMP
Fax
N/A
Employees
11
Year Founded
2006

Profitability

Net Income
$-26,480,000.00
Net Margins
-502.73%
Pretax Margin
-471.80%

Debt

Sales & Book Value

Annual Sales
$4.76 million
Book Value
($1.26) per share

Miscellaneous

Free Float
9,237,000
Market Cap
$7.26 million
Optionable
Optionable
Beta
1.27

Social Links

These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

This page (NASDAQ:ADMP) was last updated on 11/4/2024 by MarketBeat.com Staff
From Our Partners